deltatrials
Completed OBSERVATIONAL NCT00116090

Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study

Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study

Sponsor: National Eye Institute (NEI)

Conditions Cancer Immunosuppression Infection Mortality Uveitis
Updated 6 times since 2017 Last updated: Jun 30, 2017 Started: Jun 16, 2005 Completion: Apr 21, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00116090, this observational or N/A phase trial focuses on Cancer and Immunosuppression and remains completed. Sponsored by National Eye Institute (NEI), it has been updated 6 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Apr 2018 · 15 months · monthly snapshotCompleted~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed

  2. Jul 2024 — Sep 2024 [monthly]

    Completed

  3. Jan 2021 — Jul 2024 [monthly]

    Completed

  4. Jun 2018 — Jan 2021 [monthly]

    Completed

  5. Apr 2018 — Jun 2018 [monthly]

    Completed

    Phase: NA → None

▶ Show 1 earlier version

  1. Jan 2017 — Apr 2018 [monthly]

    Completed NA

    First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Eye Institute (NEI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations